Conclusion-This series confirms symptomatic improvement after DDD pacing in hypertrophic cardiomyopathy. There remains, however, a discrepancy between perceived symptomatic benefit and modest objective improvement. Furthermore, the optimal outcome has been achieved only with continued pharmacological treatment. Current methods of temporary evaluation do not predict functional outcome which seems to be independent of the magnitude of gradient reduction. (Heart 1996;75:44-49) 
Abstract
Background-DDD pacing has been advocated as an effective treatment for drug refractory obstructive hypertrophic cardiomyopathy. This study reports the outcome of pacing in 56 patients with refractory symptoms referred to four tertiary centres. Methods-Core data on symptoms, drug burden, and left ventricular outflow tract gradient were recorded. Patients underwent a temporary pacing study with optimisation of the atrioventricular (AV) delay for greatest gradient reduction without haemodynamic compromise. Patients were assessed after implantation in terms of changes in symptoms, drug load, and outflow tract gradient. Results-56 patients underwent pacing assessment. The mean (SD) left ventricular outflow tract gradient before pacing was 78 (31) mm Hg. At temporary study the mean (SD) left ventricular outflow tract gradient was 38 (24) mm Hg with a median (range) optimised sensed AV delay of 65 ms. Fifty three patients were implanted and followed up for a mean (SD) of 11 (11) months. The median (range) programmed sensed AV delay was 60 (31-200) ms. Left ventricular outflow tract gradient at follow up was 36 (25) mm Hg. Forty four patients had improved functional class. Although a correlation (r = 0.69) was shown between acute and chronic left ventricular outflow tract gradient reduction, there was no correlation between magnitude of gradient reduction and functional improvement, and no appreciable change in pharmacological burden. Conclusion-This series confirms symptomatic improvement after DDD pacing in hypertrophic cardiomyopathy. There remains, however, a discrepancy between perceived symptomatic benefit and modest objective improvement. Furthermore, the optimal outcome has been achieved only with continued pharmacological treatment. Current methods of temporary evaluation do not predict functional outcome which seems to be independent of the magnitude of gradient reduction.
(Heart 1996;75:44-49) Keywords: hypertrophic cardiomyopathy; dual chamber pacing; left ventricular outflow tract obstruction Management of patients with symptomatic obstructive hypertrophic cardiomyopathy remains problematic. Symptoms of chest pain, exertional dyspnoea, syncope, and palpitation may all require therapeutic intervention.' Current pharmacological treatment with fi adrenergic blockers, calcium channel blockers, particularly verapamil, or disopyramide may be helpful but are often ineffective or poorly tolerated. 23 Surgery in the form of transaortic septal myectomy4 or mitral valve replacement5 still carries significant mortality and associated morbidity may be significant. There is thus a need for other therapeutic strategies in this highly symptomatic group of patients.
Dual chamber pacing with a short atrioventricular delay has been the subject of increasing interest as a therapeutic option.6-8 We report our experience of acute haemodynamic evaluation of dual chamber pacing in patients with drug refractory obstructive hypertrophic cardiomyopathy and subsequent outcome at follow up.
Patients and methods

STUDY POPULATION
The study population consisted of 56 consecutive patients with hypertrophic cardiomyopathy referred to tertiary referral centres for management of drug refractory symptoms. The distribution of patient recruitment was as follows: Nancy n = 24, London n = 15, Warsaw n = 11, and Cambridge n = 6.
Hypertrophic cardiomyopathy was diagnosed on the basis of typical clinical, echocardiographic, and haemodynamic features. All patients had a left ventricular outflow tract gradient greater than 30 mm Hg at rest (n = 54) or a gradient less than 30 mm Hg at rest but with a consistently provocable gradient > 30 mm Hg (n = 2). Detailed quantitative wall thickness data were available for 51 patients. The mean diameter of the interventricular septum was 23-4 (7-7) mm, and the mean free wall was 15-5 (4.2) mm. Morphological classification, using the Maron classification,9 was available for 43 patients: one had type 1 hypertrophy, nine type 2 hypertrophy, and 33 type 3 hypertrophy. This implies that most patients had some hypertrophy of the free wall of the left ventricle, although the data suggest considerable asymmetry in its distribution.
The mean symptom duration before assessment for pacing was 7 0 (5 5 mm Hg which reduced at temporary study to a mean of 38 (24) mm Hg giving a mean reduction of 49%. The median (range) optimised sensed AV delay was 65 (25-125) ms.
Four patients did not undergo temporary study before pacemaker implantation: two because of a small resting but a consistently large provocable gradient, one because of the development of complete heart block between angiography and the temporary study, and one because of intermittent second degree heart block and associated syncope. Three patients were not implanted as a result of the temporary study: two because of failure to demonstrate haemodynamic improvement and one because the mechanism of syncope was not thought to be the result of a small left ventricular outflow tract gradient which reduced at study. PACEMAKER 
IMPLANTATION
Patients who responded at temporary study were implanted with dual chamber pacemak- (fig 1) . Angina was improved to class I status in 39 patients (75%) of the study population but 10 (19%) with symptomatic angina showed no improvement (fig 2) . Syncope was present in 22 patients before implant with presyncope/ dizziness in a further 15. At follow up three patients had sustained syncope, one of whom had not experienced syncope before pacing. Two patients described presyncope at follow up: one had previously described syncope, the other continued to experience presyncope.
In the subset of patients who underwent metabolic exercise testing there was a small but significant (P < 0 02) improvement in maximum oxygen uptake from 18-7 (3-8) ml/kg/min to 20-8 (4 6) ml/kglmin.
The mean range left ventricular outflow tract gradient before implant was 78 (31) mm Hg and at follow up was 36 (25) Acute change in LVOT gradient (mm Hg) was correlation (r = 0-69, P < 0-0001) between the values of gradient reduction with temporary pacing and the chronic reduction at follow up (fig 3) . There was no significant difference, however, in the absolute value of gradient reduction (43 (27) 
CONCOMITANT PHARMACOLOGICAL TREATMENT
There was no significant change in the overall drug burden after pacemaker implantation. Thirteen patients were introduced to /3 blocking agents or had their dosage increased, while seven were able to reduce or discontinue /3 blocking agents. Seven patients were introduced to calcium channel blockers or received an increase in dosage, whereas 13 had their dosage reduced or discontinued. Atrioventricular nodal blocking agents were specifically introduced in two patients in an attempt to slow native atrioventricular conduction and improve complete capture of the right ventricular apex. Both patients taking disopyramide discontinued the drug: one because of drug intolerance and one after septal myectomy because of failure of DDD pacing in combination with verapamil and disopyramide.
Three patients required His bundle ablation and reprogramming of their pacing systems for established (two) and paroxysmal (one) atrial fibrillation. Another problem of the temporary study is the use of haemodynamic data to guide implantation. While the left ventricular outflow tract gradient can be determined noninvasively by Doppler echocardiography, cardiac output is not so reliably obtained. At follow up more reliance is consigned to the QRS duration. Any sign of fusion on the electrocardiogram suggesting incomplete activation of the ventricles from the right ventricular apex should lead to: (i) shortening of the AV delay to regain complete ventricular capture; (ii) additional AV nodal blocking agents and/or; (iii) consideration of radiofrequency ablation of the AV node which allows programming of normal AV delays.
Discussion
EXERCISE TESTING
The improvement in symptoms reported here, as in previous studies, is mainly based on subjective assessment of patients symptoms and such subjective point assessment of symptoms may be unreliable, particularly in a disease in which daily fluctuation in symptoms is common. The placebo effect of pacemaker implantation may also contribute to subjective improvement. Assessment with maximal symptom limited exercise testing with respiratory gas analysis offers an objective basis for assessment of medical intervention in hypertrophic cardiomyopathy.'8
CONCOMITANT PHARMACOLOGICAL TREATMENT
The improvement in symptoms in this study was not obtained with pacing treatment alone and occurred with pacing in conjunction with medical treatment such as fi blockers or calcium antagonists. The drug burden was unchanged and some patients have been given increased doses of AV nodal blocking agents specifically to facilitate complete ventricular capture.
The largest previously reported series of patients paced for hypertrophic cardiomyopathy were all initially free from medication8 but after more prolonged follow up a significant proportion received drugs again.'6 Other reported experiences have continued drug treatment unchanged with one recent study also demonstrating the specific use of AV nodal blocking agents to prolong native conduction through the AV node and facilitate complete ventricular capture.'9
IMPORTANCE OF ATRIOVENTRICULAR INTERVAL PROGRAMMING
The temporary study data reveal a wide range of AV delays giving optimal haemodynamic values. This correlates with the AV delays required to produce complete right ventricular pre-excitation-the crucial requirement for success of this treatment. The variability of these values presumably reflects the variability in native conduction and in the use of AV nodal blocking drugs. In our study, the median value of the programmed sensed AV delay was 60 ms. This value is in agreement with that in European studies7 19 20 but is significantly shorter than the AV delays described by Fananapazir et al8 who reported their initial experience with DDD pacing in 44 patients free of medications for the study period. All, except five patients had AV delays of 100 ms or more. Their recently expanded series of 84 patients gives a similar distribution of AV delays with all but two patients programmed initially with an AV delay of 100 ms or greater. '6 In our joint experience, such AV delay values in the presence of normal AV conduction produce at best only partial right ventricular capture, are not associated with maximal reduction in the left ventricular outflow tract gradient, and are unlikely to induce clinical improvement.
The choice of generator was dictated by the programmable features available, individual patients specific requirements, and the spectrum of devices available in any one centre. The major criterion for selection was the ability to programme very short AV delays as our temporary studies showed haemodynamic benefit with sensed AV delays as low as 30 ms.
There are important haemodynamic differences between sensed and paced atrial events2' with equivalent left atrial-left ventricular relations when the paced AV delay is significantly longer than the sensed AV delay.22 The implication is that while paced AV delays of 100-125 ms may produce complete right ventricular pre-excitation the equivalent sensed AV delays are usually 50-100 ms shorter, highlighting the need for pacemakers with ultra-short AV delays.
MECHANISMS OF IMPROVEMENT
Symptomatic improvement after DDD pacing in patients with obstructive hypertrophic cardiomyopathy is thought to be related to the decrease in left ventricular outflow tract gradient. The mechanism of obstruction is still not perfectly understood but the most favoured mechanism postulates that blood passing at increased velocity through the narrowed left ventricular outflow tract creates Venturi forces causing systolic anterior motion of the mitral valve and impaired closure leading to outflow tract obstruction and a variable degree of mitral regurgitation.23
The most commonly accepted mechanism of gradient reduction after pacing in hypertrophic cardiomyopathy remains inversion of the ventricular contraction sequence as a consequence of right ventricular apical activation mimicking left bundle branch block leading to: (i) widening of the left ventricular outflow tract; (ii) a decrease in the Venturi effect; and (iii) a decrease in systolic anterior motion of the mitral valve. To maintain efficacy it is paramount that the ventricles are permanently and completely activated from the right ventricular apical pacing site.
Apical pre-excitation of the right ventricle which mimics left bundle branch block is probably not the only explanation for gradient reduction as pacing has been reported to decrease the outflow tract gradient and give symptomatic relief in patients with pre-existing left bundle branch block.16 However, the pattern of ventricular activation in patients with left bundle branch block does not exactly mimic the pattern induced by pacing with right ventricular apical capture.24 Another explanation is that gradient reduction occurs as a consequence of reduced systolic function with chronic chamber dilatation as a potentially deleterious long-term effect. 25 Speculation on the mechanism of benefit has focused on the left ventricular outflow tract gradient and its reduction with pacing. Hypertrophic cardiomyopathy is a condition in which diastolic function is abnormal and may be an important cause of symptoms. Previous work on the effect of short AV delay pacing on diastolic function has drawn different conclusions. Acute studies with cardiac catheterisation or Doppler echocardiography have demonstrated worsened diastolic parameters,2627 whereas work using nuclear medicine techniques have demonstrated some improvements in filling parameters28 and cited these as a possible mechanism of benefit. The numbers studied to date are small and further information will come from ongoing randomised crossover trials of DDD pacing. ROLE Myectomy produces a greater reduction in left ventricular outflow tract gradient than pacing (87%30 v 50%78). It is considered that myectomy is unlikely to be successful unless the residual gradient is small. It is unclear whether the larger residual gradient after successful DDD pacing is important. Nevertheless, it seems appropriate to pursue evaluation of dual chamber pacing as a low risk therapeutic intervention in patients with symptomatic hypertrophic cardiomyopathy.
LIMITATIONS OF STUDY
This study adds to the published anecdotal experience of pacing in patients with hypertrophic cardiomyopathy, although the multicentre nature of the experience brings with it varying clinical practice. Specifically, the choice of pharmacological approach and pacemaker prescription were determined by local factors.
The true role of DDD pacing in the management of obstructive hypertrophic cardiomyopathy requires properly designed randomised controlled studies with detailed characterisation of the trial population and objective assessment of benefit. Such studies are under way in Europe and America and will undoubtedly advance our knowledge of the mechanism of benefit of DDD pacing in hypertrophic cardiomyopathy, provide greater objective evidence of such benefit, and aid identification of those patients most likely to benefit from DDD pacing.
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